|Bid||130.57 x 800|
|Ask||130.66 x 800|
|Day's Range||127.50 - 130.98|
|52 Week Range||101.30 - 147.42|
|Beta (3Y Monthly)||1.24|
|PE Ratio (TTM)||12.55|
|Forward Dividend & Yield||1.60 (1.25%)|
|1y Target Est||N/A|
It's an odd development to say the least, but a development nonetheless. Federal judge Richard Leon is attempting to prevent the merger of drugstore chain CVS Health (NYSE:CVS) and health insurer Aetna, even though the merger has already been consummated, with Aetna's value being folded into the price of CVS stock in late November.Source: Mike Mozart via FlickrAlthough rare, companies have been forced to unwind completed mergers before. They've never been forced to do so using Tunney Act proceedings, however, and legal experts doubt Leon's efforts will gain much traction.They could prove to be a drag on the CVS story, however, which is already lugging around too much dead weight.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Stocks to Buy That Wall Street Expects to Soar for the Rest of 2019 Healthcare Mergers Are CommonIt's not the first melding of unlike healthcare organizations we've seen of late. Cigna (NYSE:CI) now owns Express Scripts, and HCA Healthcare (NYSE:HCA) has completed its purchase of Asheville, North Carolina's Mission Health. Even Amazon.com (NASDAQ:AMZN), JPMorgan Chase (NYSE: JPM) and Berkshire Hathaway (NYSE:BRK.B) are teaming up to create a new healthcare outfit intended to cost-effectively serve all three organizations' employees.The common thread among these and dozens of other similar partnerships, of course, is an effort to combat the rising costs of providing healthcare. In most instances, the pairings were allowed to take shape with little fanfare.For reasons that remain mostly unclear, however, this particular deal has prompted a judicial pushback. District Judge Richard Leon's Merger HistoryThe name Richard Leon may ring a bell with some investors. The U.S. district judge is the same that oversaw the Department of Justice's effort to quell the merger of AT&T (NYSE:T) and Time Warner.Leon was largely criticized following his ruling, not just for allowing it to take shape, but for allowing it to take shape without adding any conditions.That's not his only controversial case, however. Indeed, Leon has left a trail of controversial (and often overturned) rulings behind in his career, including politically-charged ones.And, while it would be easy to chalk the judge up as a politically-motivated hack, it would also be unfair; he's proven helpful to not just both political parties, but both philosophical schools of thought. The AT&T deal with Time Warner raises many of the same concerns being raised by the union of Aetna and CVS.The crux of the still-unanswered question is the consent decree that calls for CVS to sell its Medicare Part D business to WellCare Health Plans (NYSE:WCG), while still remaining WellCare's pharmacy benefits manager. Leon's concern "is whether or not the pharmaceuticals will be [offered to WellCare customers] at a lower price and whether they're going to be more readily accessible."Still, to kill the deal at this point would step far out of the bounds of the consent decree process as it's been established. It would also step out of the accepted bounds of Tunney Act hearings. At best, says former DOJ antitrust attorney Andrea Agathoklis Murino, Leon "can say the remedy was insufficient," forcing CVS to do more than simply shed its Medicare D arm. Bottom Line for CVS StockThe development makes for thrilling headlines, though Leon's lacking legal teeth if his intent is to undo what's already been done. All the same, the renewed court battle which could last well into the summer not only serves as a nuisance but keeps shareholders uncertain as to what the company may look like a year from now. That, in turn, is keeping the value of an already-beaten-down CVS stock suppressed.What's largely being overlooked in the legal melee, however, is that such a worst-case scenario has already been more than priced in.As of its most recent look, CVS stock is trading at a dirt cheap forward-looking P/E ratio of 7.6. Even if Aetna and CVS are forced to completely split again, which is unlikely, CVS remains one of the top remaining players in the pharmacy and PBM space, if for no other reason than attrition of its rivals. The more plausible outcome of a deeper separation of its Medicare business, ultimately, could prove to go unnoticed by investors.It's certainly a trade against the current grain but surrounded by doubts and questions, CVS stock looks like a compelling contrarian trade here for investors willing to hunker down for the long haul.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 10 Stocks to Buy That Wall Street Expects to Soar for the Rest of 2019 * 7 Value Stocks That Are Flying Under the Radar * 6 Mouth-Watering Fast Food Stocks for Growth Investors Compare Brokers The post Aetna Uncertainty Is Keeping CVS Stock Way Undervalued appeared first on InvestorPlace.
Building these facilities can be part of a larger strategy of following population growth — and more.
Nashville is home to some of the largest employers of nurses in the country, but for nurses actually working in the “nation’s health care capital” it has become increasingly difficult to buy a house. Nashville home prices have risen by 75% since 2008, from a median price of $161,191 to $285,000, according to a new study by real estate data firm PropertyShark. To see where Nashville ranked among the 10 toughest home-buying markets for nurses, check out the slideshow with this story.
Riding high on its restructuring initiative and growth strategy, Community Health (CYH) holds immense potential to reap benefits for investors.
HCA Healthcare Inc NYSE:HCAView full report here! Summary * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for HCA with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting HCA. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold HCA had net inflows of $3.65 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
HCA Healthcare Inc. filed paperwork with the Securities and Exchange Commission Thursday that could help the Nashville-based company raise some serious cash. The hospital giant will offer $4.9 billion of senior secured notes with the intent to use proceeds for “general corporate purposes and the redemption of certain outstanding indebtedness,” according to the filing. While Thursday’s filing does not mention using proceeds for expansion, the filing that accompanied the January notes said those proceeds could be used for acquisitions.
The government requires hedge funds and wealthy investors that crossed the $100 million equity holdings threshold are required to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings level the playing field for ordinary investors. The latest round of 13F filings disclosed the […]
Ensign Group (ENSG) purchases the assets of Preceptor Health Care and the real estate and operations of Golden Palms Rehabilitation and Retirement.
Moody's Investors Service (Moody's) assigned a Baa3 rating to HCA Inc.'s new senior secured notes. HCA Inc. is a wholly owned subsidiary of HCA Healthcare, Inc. (collectively "HCA" or the company). There is no change to any of the company's existing ratings, including the Ba1 Corporate Family Rating (CFR), or its stable outlook.
Solid segmental contributions bode well for Universal Health's (UHS) growth. However, elevated expenses are a lingering concern.
On 31 March 2019, HCA Healthcare, Inc. (NYSE:HCA) released its earnings update. Generally, analyst forecasts seem...
“In health care, traditionally we are taught to be safe, we are regulated and taught not to be creative, but over time that will stifle innovation,” Sen. Bill Frist said. “I would argue that health care has a lot to learn from the music world.”
Riding high on a solid revenue base and inorganic growth profile, WellCare Health (WCG) holds high potential to reap benefits for investors.
Riding high on rising revenues and inorganic growth story, HCA Healthcare (HCA) looks promising enough to garner benefits for investors.
Football fans know that Nashville is home to the Titans of the National Football League, but according to a recent Forbes report, several titans of the business world also call Music City home. Forbes has released its 2019 Forbes Global 2000 — a list of the 2,000 largest public companies in the world — and four Middle Tennessee-based companies made the cut, led by HCA Healthcare Inc.
The healthcare sector performed well in 2018, driven by positive growth in sub-segments such as medical devices, health insurance, hospitals, nursing homes, and pharmaceuticals, which offset losses in biomedical and genetics, home healthcare, medical, and dental supplies. Moving ahead into 2019, as the decade-long expansion faces a period of heightened volatility and risk, the health care sector should benefit from a shift towards more defensive sectors. In a recent sector roundup from Charles Schwab, the firm rated health care at "outperform," citing the group’s strong balance sheets, attractive dividend yields, and improved cost structure.